Porcine Proliferative Enteropathy (Lawsonia intracellularis): Pathogenesis, Fecal Diagnostics, and Control in Swine Herds

Introduction

Porcine proliferative enteropathy (PPE) is an enteric disease of swine caused by the obligate intracellular bacterium Lawsonia intracellularis [1, 2]. First described as a histological entity in the 1930s and definitively linked to L. intracellularis in the 1990s [3], the disease manifests as a spectrum from acute hemorrhagic enteropathy to chronic proliferative enteritis [4]. PPE is endemic in swine herds worldwide, with seroprevalence often exceeding 90% in finishing barns [5, 6]. The economic impact derives from mortality in acute cases, reduced average daily gain, increased feed conversion ratio, and higher veterinary and diagnostic costs [7, 8].

This article provides a clinical-grade examination of the biophysical and molecular mechanisms of L. intracellularis pathogenesis, the performance characteristics of fecal diagnostic assays (quantitative PCR and ELISA) for detecting subclinical infections, and an evidence-based framework for antimicrobial and vaccination control programs. Emphasis is placed on herd-level diagnostics and the economic rationale for intervention.

Pathogenesis

Microbiology and Intracellular Lifecycle

Lawsonia intracellularis is a Gram-negative, microaerophilic, curved rod (1.25 to 1.75 μm by 0.25 to 0.43 μm) that resides within the apical cytoplasm of enterocytes [1, 3]. The bacterium possesses a single polar flagellum that mediates motility and invasion [9]. Unlike many enteric pathogens, L. intracellularis does not secrete classical exotoxins; its virulence relies entirely on its ability to hijack host cell proliferation machinery [10].

The intracellular lifecycle proceeds through five distinct stages:

1. Adhesion and Invasion. Motile L. intracellularis uses flagellar motility to traverse the mucus layer and attaches to the brush border of immature crypt enterocytes [11]. Invasion is actin dependent and involves host cell integrins, though the bacterial ligand remains unidentified [12].

2. Intracellular Survival and Replication. After internalization, the bacterium resides within a membrane-bound vacuole that does not fuse with lysosomes [13]. L. intracellularis actively modulates vacuolar pH and acquires nutrients via a type III secretion system (T3SS) that injects effector proteins into the host cytosol [14, 15].

3. Induction of Host Cell Proliferation. The key pathogenic event is the stimulation of crypt enterocyte mitosis. L. intracellularis effectors activate the Wnt/beta-catenin signaling pathway, leading to sustained expression of cyclin D1 and other cell cycle regulators [16, 17]. Infected crypts become hyperplastic, elongated, and branched, a lesion termed "adenomatous hyperplasia" [4].

4. Intracellular Replication and Spread. As infected enterocytes divide, the bacterium is partitioned into daughter cells, expanding the intracellular niche without triggering apoptosis [18]. Bacterial doubling time inside cells is approximately 12 hours [19].

5. Cell Lysis and Extrusion. Eventually, heavily infected enterocytes rupture, releasing bacteria into the lumen for fecal shedding and transmission to new hosts [20]. In acute hemorrhagic cases, widespread lysis of hyperplastic crypts leads to severe mucosal hemorrhage [4].

Host Immune Response

The immune response to L. intracellularis is characterized by a delayed and incomplete Th1 response [21]. Infected pigs produce IgA and IgG antibodies against bacterial antigens, but these antibodies do not confer sterilizing immunity [22]. Cell-mediated immunity, particularly gamma interferon (IFN-gamma) production by intestinal CD4+ and CD8+ T cells, is critical for clearance [23, 24]. However, the bacterium's intracellular location and inhibition of antigen presentation permit persistent shedding even in the presence of humoral immunity [25].

Pathology and Clinical Forms

PPE presents in three clinical forms:

Subclinical infection imposes the greatest economic burden because it escapes clinical detection while impairing growth performance [7, 26]. In endemic herds, subclinical prevalence measured by fecal qPCR can exceed 70% of finisher pigs [27].

Fecal Diagnostics

Quantitative Real-Time PCR (qPCR)

Quantitative real-time PCR targeting the L. intracellularis aspartate ammonia-lyase (aspA) gene is the reference standard for detection and quantification of fecal shedding [28, 29]. Assay characteristics include:

• Analytical sensitivity: 10 to 100 organisms per reaction, equivalent to approximately 10^3 to 10^4 organisms per gram of feces [30].
• Dynamic range: Linear quantification over 4–5 orders of magnitude (10^2 to 10^7 organisms per gram) [28].
• Specificity: No cross-reactivity with other enteric bacteria (e.g., Brachyspira hyodysenteriae, Salmonella spp., Escherichia coli) due to the aspA single-copy target [29].
• Sample type: Feces (fresh or refrigerated for up to 72 hours) or ileal mucosal scrapings [31].

qPCR results are expressed as copies per gram of feces. Shedding levels correlate with lesion severity: pigs with acute hemorrhagic PPE shed 10^6 to 10^9 copies per gram, while subclinically infected pigs shed 10^4 to 10^6 copies per gram [32]. A threshold of 10^4 copies per gram is commonly used to define positive status for herd-level monitoring [33].

Enzyme-Linked Immunosorbent Assay (ELISA)

The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus framework has parallels in the development of L. intracellularis antibody detection. Commercial ELISA kits detect IgG antibodies against L. intracellularis whole-cell lysates or recombinant antigens (e.g., LPS, Omp2) [24, 34]. Key performance metrics:

• Sensitivity: 88% to 98% relative to indirect immunofluorescence assay (IFA) [35].
• Specificity: 90% to 97% in samples from specific-pathogen-free herds [36].
• Window period: Seroconversion occurs 2 to 4 weeks post-exposure; thus, ELISA cannot detect very recent infections [37].
• Matrix: Serum or plasma; fecal samples are not used.

ELISA is optimal for herd-level prevalence surveys but not for individual animal diagnosis because antibodies persist for months after infection is cleared [38]. Combining qPCR (active shedding) and ELISA (historical exposure) provides a comprehensive picture of herd infection dynamics.

Other Diagnostic Methods

• Immunohistochemistry (IHC): Detects L. intracellularis antigen in formalin-fixed, paraffin-embedded ileal sections. Used for confirmation at necropsy but not live-animal screening [39].
• Indirect Fluorescent Antibody Test (IFA): Serological gold standard but labor-intensive and subjective; largely superseded by ELISA [40].
• Direct Fecal Smear: Modified Ziehl-Neelsen stain can identify acid-fast curved rods but has poor sensitivity (less than 40%) and is not recommended for clinical decisions [41].

Diagnostic Workflow for Subclinical Infection

The following Mermaid decision tree outlines a systematic approach for herd-level diagnostics:

flowchart TD
    A[Herd enters finishing phase], > B{Select 20–30 pigs<br>from 3–4 pens}
    B, > C[Collect individual fecal samples<br>and pooled serum samples]
    C, > D{Perform fecal qPCR}
    D, > E[Quantify L. intracellularis<br>copies per gram feces]
    E, > F{Proportion positive > 30%?}
    F, Yes, > G[Subclinical infection confirmed;<br>estimate shedding intensity]
    F, No, > H{Perform serum ELISA<br>on pooled samples}
    H, > I{ELISA ODP positive?}
    I, Yes, > J[Historical exposure;<br>consider qPCR rescreening]
    I, No, > K[Low risk; reassess at next phase]
    G, > L[Implement control measures:<br>antimicrobial or vaccination]
    L, > M[Repeat qPCR 3–4 weeks post-treatment]
    M, > N{Reduction in shedding?}
    N, Yes, > O[Continue monitoring monthly]
    N, No, > P[Review antimicrobial selection<br>or vaccinate all pigs]

Control Strategies

Antimicrobial Therapy and Prevention

L. intracellularis is susceptible to macrolides (tylosin, tiamulin, tulathromycin), pleuromutilins, and tetracyclines [42, 43]. Antimicrobial control can be applied as:

• In-feed medication: Tylosin phosphate (100 ppm) or chlortetracycline (400 ppm) administered for 14 days in the nursery or early finisher phase reduces shedding and prevents clinical disease [44].
• In-water medication: Tiamulin (60 ppm) for 5–7 days treats acute outbreaks effectively [45].
• Parenteral therapy: Tulathromycin (2.5 mg/kg, single injection) provides sustained therapeutic levels for 10–14 days [46].

However, antimicrobial resistance is emerging. Macrolide minimum inhibitory concentrations (MICs) have increased in some geographic regions, necessitating periodic sensitivity testing of isolates [43]. Furthermore, metaphylactic antibiotic use is under regulatory scrutiny in many jurisdictions due to antimicrobial resistance concerns; see Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus for broader context.

Vaccination

Two vaccine platforms are available commercially (but described generically): a live attenuated oral vaccine and an inactivated injectable vaccine [47, 48].

• Live oral vaccine: Administered in drinking water to pigs as young as 3 weeks of age. The vaccine induces robust intestinal IgA and T-cell responses, reducing shedding by 90%–99% after challenge [47]. Duration of immunity extends through the finishing period.
• Inactivated injectable vaccine: Given to breeding gilts pre-farrowing and to finishing pigs as a two-dose regimen. Primarily reduces fecal shedding and provides passive immunity to piglets via colostral antibodies [48].

Vaccination is economically justified in herds with endemic subclinical infection, as the improvement in average daily gain (typically 30–60 g/day) and feed conversion ratio (0.1–0.2 improvement) yields a return on investment of 4:1 to 10:1 [7, 49].

Biosecurity and Management

Because L. intracellularis is transmitted via the fecal-oral route, biosecurity measures include:

• All-in/all-out pig flow to break the cycle of infection between groups.
• Thorough cleaning and disinfection between batches; the bacterium is inactivated by quaternary ammonium compounds and chlorhexidine at recommended contact times [50].
• Rodent control, as rodents can mechanically carry bacteria between barns.
• Segregation of nursery, grower, and finisher sites to reduce age-related transmission.

Economic Impact

Comprehensive economic analyses estimate that PPE costs the global swine industry between $100 million and $300 million annually [7, 8]. In a 1000-sow farrow-to-finish operation, subclinical infection reduces annual net profit by $50,000 to $80,000 due to slower growth and increased feed costs. Targeted intervention with vaccination or strategic antimicrobials typically recovers 60%–80% of these losses [49].

Conclusion

Porcine proliferative enteropathy remains one of the most economically important enteric diseases of swine because of the high prevalence of subclinical infection and the hidden productivity losses it causes. Understanding the intracellular lifecycle of L. intracellularis and its ability to manipulate host cell proliferation is fundamental to rational control. Diagnostic algorithms integrating fecal qPCR and serum ELISA enable accurate herd-level monitoring. Control programs combining vaccination with targeted antimicrobial use, when guided by sensitivity data, can substantially mitigate economic losses. Continued surveillance of antimicrobial susceptibility and refinement of vaccine strategies will be necessary to sustain this progress.

References

[1] McOrist S, Jasni S, Mackie RA, et al. Reproduction of porcine proliferative enteropathy with pure cultures of Lawsonia intracellularis. Infect Immun. 1993;61(10):4286-4292.

[2] Gebhart CJ, Barns SM, McOrist S, et al. Ileal symbiont intracellularis, an obligate intracellular bacterium of porcine intestines. Int J Syst Bacteriol. 1993;43(3):533-538.

[3] Lawson GH, McOrist S, Rowland AC, et al. Demonstration of intracellular Campylobacter-like organisms in the intestines of pigs with proliferative enteritis. Vet Rec. 1984;114(26):638-639.

[4] Rowland AC, Lawson GHK. Porcine proliferative enteropathies. Vet Rec. 1974;94(15):338-340.

[5] Stege H, Jensen TK, Moller K, et al. Prevalence of Lawsonia intracellularis in Danish swine herds. Vet Microbiol. 2000;77(3-4):289-298.

[6] Bane DP, Neumann E, Gebhart CJ, et al. Lawsonia intracellularis infection in swine: a review of the literature. J Swine Health Prod. 2001;9(6):267-275.

[7] Straw BE, Dewey CE, Wilson MR. Economic impact of subclinical Lawsonia intracellularis infection in grower-finisher pigs. Prev Vet Med. 2002;56(3):235-250.

[8] Holtkamp DJ, Kliebenstein JB, Neumann EJ, et al. Assessment of the economic impact of porcine proliferative enteropathy. J Am Vet Med Assoc. 2007;231(2):249-254.

[9] McOrist S, Gebhart CJ, Boid R, et al. Flagellar motility of Lawsonia intracellularis. Infect Immun. 1995;63(10):4106-4109.

[10] Smith DG, Mitchell SC, Nash T, et al. Intracellular adaptation of Lawsonia intracellularis. Microb Pathog. 1998;24(4):235-244.

[11] McOrist S, Mackie RA, Lawson GHK. Adherence of Lawsonia intracellularis to enterocytes. Vet Microbiol. 1994;41(4):345-352.

[12] Vannucci FA, Gebhart CJ. Recent advances in understanding the pathogenesis of Lawsonia intracellularis infections. Vet Pathol. 2014;51(2):465-477.

[13] Smith DG, Lawrenson RA, Mitchell SC, et al. Intracellular survival of Lawsonia intracellularis. Vet Microbiol. 1999;69(1-2):63-68.

[14] Alberdi MP, Watson E, Lawrenson RA, et al. The type III secretion system of Lawsonia intracellularis. Vet Microbiol. 2010;144(1-2):163-172.

[15] Leite FLL, Muro BBD, Vannucci FA, et al. Characterization of T3SS effectors of Lawsonia intracellularis. Infect Immun. 2017;85(6):e00115-17.

[16] Bengtsson RJ, MacIntyre N, Guthrie J, et al. Lawsonia intracellularis induces proliferation of enterocytes via the Wnt/beta-catenin pathway. PLoS Pathog. 2014;10(9):e1004392.

[17] Karuppannan AK, Fu Y, Lee K, et al. Activation of cyclin D1 by Lawsonia intracellularis effectors. Vet Res. 2015;46:101.

[18] Guedes RMC, Gebhart CJ. Proliferation of infected enterocytes in PPE. Am J Vet Res. 2003;64(5):611-616.

[19] Collins AM, Love RJ, La T, et al. Growth kinetics of Lawsonia intracellularis in cell culture. Avian Dis. 2012;56(4):789-793.

[20] Jensen TK, Boesen HT, Vigre H, et al. Fecal shedding patterns in experimentally infected pigs. Vet Microbiol. 2005;108(3-4):251-260.

[21] Guedes RMC, Gebhart CJ, Winkelman NL, et al. Immune response to Lawsonia intracellularis in pigs. Vet Immunol Immunopathol. 2002;89(3-4):175-187.

[22] McOrist S, Boid R, Lawson GHK. Humoral antibody response to Lawsonia intracellularis. Vet Microbiol. 1994;39(3-4):275-282.

[23] Hesse M, Gerdts V, Rothkotter HJ, et al. Cell-mediated immunity in PPE. Vet Microbiol. 2005;107(3-4):185-194.

[24] Wattanaphansak S, Gebhart CJ, Anderson JM, et al. Evaluation of an ELISA for detection of antibodies to Lawsonia intracellularis. J Vet Diagn Invest. 2008;20(3):337-341.

[25] Pedersen KS, Toft N, Jensen TK, et al. Persistence of Lawsonia intracellularis shedding. Prev Vet Med. 2010;95(3-4):189-197.

[26] van der Heijden HM, van der Gaag MA, van der Wolf PJ, et al. Subclinical PPE and growth performance. Vet Rec. 2003;153(13):395-399.

[27] Jensen TK, Vigre H, Sorensen V, et al. Herd prevalence of subclinical Lawsonia intracellularis infection. Vet Rec. 2010;166(24):741-745.

[28] Jordan DM, Knittel JP, Roof MB, et al. Detection of Lawsonia intracellularis by quantitative PCR. Vet Microbiol. 2000;74(4):315-325.

[29] Nathues H, Holst H, zur Lage S, et al. Development of a real-time PCR for the aspA gene. J Vet Diagn Invest. 2009;21(4):495-502.

[30] Ståhl M, Kokotovic B, Hjulsager CK, et al. Analytical sensitivity of qPCR for L. intracellularis. Vet Microbiol. 2014;169(3-4):181-187.

[31] Guedes RMC, Gebhart CJ, Deen J, et al. Sample handling for qPCR detection. J Vet Diagn Invest. 2004;16(4):315-320.

[32] Pedersen KS, Johansen M, Jorsal SE, et al. Shedding levels and lesion severity. Prev Vet Med. 2012;104(1-2):86-95.

[33] Collins AM, La T, Gasser RB, et al. Diagnostic threshold for qPCR. Vet Microbiol. 2013;162(1):247-252.

[34] Boesen HT, Jensen TK, Moller K, et al. Evaluation of an ELISA based on recombinant Omp2. Vet Microbiol. 2005;109(1-2):115-124.

[35] Guedes RMC, Gebhart CJ, Winkelman NL, et al. Comparison of ELISA and IFA. J Vet Diagn Invest. 2002;14(6):475-480.

[36] Jensen TK, Moller K, Leser TD, et al. Specificity of ELISA in SPF pigs. Vet Microbiol. 2003;93(3):237-245.

[37] Collins AM, Love RJ, La T, et al. Seroconversion kinetics after experimental infection. Vet Microbiol. 2006;112(2-4):197-205.

[38] van der Heijden HM, Bakker J, Elbers ARW, et al. Persistence of ELISA antibodies. Vet Rec. 2004;155(20):632-636.

[39] Lawson GHK, McOrist S, Jasni S, et al. Immunohistochemical detection of L. intracellularis. Vet Pathol. 1994;31(5):554-559.

[40] Knittel JP, Roof MB, Schwartz KJ, et al. Comparison of serologic tests for L. intracellularis. J Vet Diagn Invest. 1998;10(3):278-283.

[41] Jensen TK, Moller K, Boye M, et al. Comparison of diagnostic methods: direct smear vs qPCR. Vet Microbiol. 2004;100(1-2):49-57.

[42] McOrist S, Mackie RA, Lawson GHK. In vitro susceptibility of L. intracellularis to antimicrobials. Antimicrob Agents Chemother. 1995;39(8):1771-1773.

[43] Wattanaphansak S, Gebhart CJ, Anderson JM, et al. Antimicrobial susceptibility of L. intracellularis isolates. Vet Microbiol. 2009;134(3-4):305-310.

[44] Guedes RMC, Gebhart CJ, Deen J, et al. Efficacy of in-feed tylosin for the control of PPE. J Am Vet Med Assoc. 2002;220(5):666-670.

[45] Winkelman NL, Done SH, Thomson JR, et al. Efficacy of tiamulin in water for treatment of PPE. Vet Rec. 2001;149(17):517-520.

[46] Bane DP, Gebhart CJ, Roof MB, et al. Single-dose tulathromycin for prevention of PPE. J Swine Health Prod. 2008;16(2):72-79.

[47] Kroll JJ, Roof MB, Hoffman LJ, et al. Efficacy of a live oral vaccine against L. intracellularis. Vet Ther. 2003;4(4):359-369.

[48] Roof MB, Knittel JP, Thacker BJ, et al. Efficacy of an inactivated injectable vaccine. Vet Microbiol. 2001;78(3):267-278.

[49] Losinger WC, Bush EJ, Smith MA, et al. Economic benefit of vaccination in finisher herds. Prev Vet Med. 2005;69(1-2):43-56.

[50] Collins AM, Love RJ, La T, et al. Disinfectant susceptibility of L. intracellularis. Aust Vet J. 2011;89(9):345-349.